Marc Tessier-Lavigne, Director at Denali Therapeutics Inc. (DNLI), sold 100,000 shares at $57.60 ($5.7M) on 2021-04-01, disclosed to the SEC on 2021-04-05.
Open-market sale of $5.7M DNLI by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $55.61 | 14,223 | $791K | 14.0% |
| 2 | $55.61 | 14,223 | $791K | 14.0% |
| 3 | $56.91 | 29,593 | $1.7M | 29.7% |
| 4 | $56.91 | 29,593 | $1.7M | 29.7% |
| 5 | $57.60 | 6,184 | $356K | 6.3% |
| 6 | $57.60 | 6,184 |
| $356K |
| 6.3% |
| Total | $56.63 avg | 100,000 | $5.7M | 100% |
| Filing → |
| REGN | SELL | 2022-10-03 | $10.2M | — | Filing → |
| DNLI | SELL | 2022-09-30 | $1.2M | — | Filing → |
| DNLI | SELL | 2022-08-25 | $632K | — | Filing → |